Filgrastim
Explore a selection of our essential drug information below, or:
Identification
- Summary
Filgrastim is a form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio
- Generic Name
- Filgrastim
- DrugBank Accession Number
- DB00099
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli.8 Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood.10 It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy.8
Filgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications.3 Tbo-filgrastim was approved by the FDA on August 29, 2012.9 Filgrastim-sndz was approved on March 6, 2015 12 and filgrastim-ayow was approved on March 2, 2022.13 A long-acting, pegylated G-CSF, pegfilgrastim, was made available to increase the duration of action of the drug.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Haematopoietic growth factors - Protein Structure
- Protein Chemical Formula
- C845H1339N223O243S9
- Protein Average Weight
- 18800.0 Da (approximate)
- Sequences
>Protein sequence MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA PLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ QMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
Download FASTA FormatReferences:
- KEGG DRUG: Filgrastim [Link]
- Synonyms
- Filgrastim
- Filgrastim-aafi
- Filgrastim-sndz
- G-CSF
- Granulocyte Colony Stimulating Factor
- Tbo-filgrastim
Pharmacology
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.8
Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia.8
Filgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.8
Filgrastim is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.8
Filgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.8
Filgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Congenital neutropenia •••••••••••• Management of Cyclic neutropenia •••••••••••• Prevention of Febrile neutropenia •••••••••••• ••••••••••• •••••••••••• Management of Hematopoietic subsyndrome of acute radiation syndrome •••••••••••• Prevention of Infection •••••••••••• ••••••••••• •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Filgrastim is used to reduce the incidence, severity and duration of neutropenia and febrile neutropenia in patients undergoing cytotoxic chemotherapy. In clinical trials in patients, filgrastim reduced the duration of febrile neutropenia, antibiotic use, and hospitalization after induction chemotherapy for acute myelogenous leukemia or myeloablative therapy followed by bone marrow transplantation; however, the incidence of fever and documented infections were not reduced in either setting.10
Filgrastim is also used to mobilize hematopoietic progenitor cells into the peripheral blood in order to reduce the risk for bleeding complications and the need for platelet transfusions. Recipients of allogeneic PBPCs mobilized with filgrastim experienced significantly more rapid hematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.10
Filgrastim causes a dose-dependent increase in circulating neutrophil counts within 24 hours of administration. Filgrastim can also cause a minor increase in monocyte and lymphocyte counts, but the clinical significance of these effects is unknown.8 In some patients, filgrastim also caused a minor increase in the number of circulating eosinophils and basophils relative to baseline; however, these patients may already have had elevated eosinophils and basophils prior to filgrastim treatment. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within one to two days, and to normal levels within one to seven days. As with other hematopoietic growth factors, G-CSF has shown in vitro stimulating properties on human endothelial cells.10
- Mechanism of action
Neutrophils are critical granulocytes involved in the acute inflammatory response and host defences against bacterial infections.5 They also contribute to long-term adaptive immunity by promoting immediate host immune response and attracting other cells, such as macrophages and dendritic cells. As neutrophils promote both the initiation and the maintenance of inflammation at sites of infection, suppressed neutrophil responses lead to extreme susceptibility to infection.2 Low neutrophil levels, or neutropenia, caused by chronic neutropenia, myelosuppressive chemotherapy, and radiation therapy increases the risk of infection and related events.4 Neutropenia caused by chemotherapy or radiation therapy can further progress into febrile neutropenia, which is associated with an elevated risk for life-threatening systemic infections and chemotherapy-associated morbidity and mortality.1
The production and release of functional neutrophils from the bone marrow are normally regulated by granulocyte colony-stimulating factors (G-CSF), which are major cytokine regulators of neutrophilic granulocytes.2 G-CSFs act on hematopoietic cells by binding to specific cell surface receptors to stimulate the proliferation‚ differentiation‚ and maturation of neutrophil progenitors. G-CSF also induces some end-cell functional activation of neutrophils, including enhanced phagocytic ability‚ priming of the cellular metabolism associated with respiratory burst‚ antibody-dependent killing, and the increased expression of some cell surface antigens.8 Filgrastim is a short-acting recombinant G-CSF that mimics the biological actions of endogenous G-CSF. It also facilitates the release of neutrophils from the bone marrow into the blood to reduce the incidence of infection and manage neutropenia.3,4
Target Actions Organism AGranulocyte colony-stimulating factor receptor stimulatorHumans - Absorption
Filgrastim exhibits nonlinear pharmacokinetics. Subcutaneous administration of 3.45 mcg/kg and 11.5 mcg/kg of filgrastim resulted in maximum serum concentrations of 4 and 49 ng/mL‚ respectively‚ within 2 to 8 hours.
Continuous 24-hour intravenous infusions of 20 mcg/kg over an 11 to 20-day period produced steady-state serum concentrations of filgrastim with no evidence of drug accumulation. The absolute bioavailability of filgrastim after subcutaneous administration is 60% to 70%.8
- Volume of distribution
After intravenous administration, the volume of distribution averaged 150 mL/kg.8 There is no evidence of drug accumulation.10
- Protein binding
There is limited information available.
- Metabolism
Like other G-CSF compounds, filgrastim is cleared from plasma via neutrophil-mediated clearance involving internalization via G-CSF receptors and degradation within the neutrophil. Filgrastim is also subject to extracellular proteolytic degradation by neutrophil elastase: this enzyme rapidly cleaves filgrastim and renders it inactive.6,7
- Route of elimination
There is limited information available; however, filgrastim is subject to renal elimination.7
- Half-life
After intravenous administration, the elimination half-life of filgrastim was approximately 3.5 hours in both normal subjects and patients with cancer. Single parenteral doses or daily intravenous doses‚ over a 14-day period‚ resulted in comparable half-lives. The half-lives were similar for intravenous administration (231 minutes‚ following doses of 34.5 mcg/kg) and for subcutaneous administration (210 minutes‚ following filgrastim dosages of 3.45 mcg/kg).8
- Clearance
Clearance rates of filgrastim were approximately 0.5 to 0.7 mL/minute/kg after intravenous administration.8
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
The oral LD50 in mouse and rat was >3 mg/kg. The intravenous LD50 in rat was also >3 mg/kg.11
There is limited information regarding filgrastim overdose. The maximum tolerated dose of filgrastim has not been determined. In clinical trials of patients with cancer receiving myelosuppressive chemotherapy‚ white blood cell counts greater than 100,000/mm3 have been reported in less than 5% of patients‚ but were not associated with any reported adverse clinical effects. Patients in the bone marrow transplantation studies received up to 138 mcg/kg/day without toxic effects‚ although there was a flattening of the dose response curve above daily doses of greater than 10 mcg/kg/day.8
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBleomycin The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin. Cyclophosphamide The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide. Topotecan The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan. Vinblastine The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine. Vincristine The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Biocilin / Biofigran / Biofilgran / Endufil / Filatil / Filgen / Gran / Granulokine / Grimatin / Inmunef / Jiexin / Leucogen / Leucostim / Macroleuco / Neukine / Neutromax / Neutroval (Sicor Biotech) / Recombicyte / SciLocyte / Tevagastrim / White-C / Zarzio
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Accofil Injection, solution 70000000 U/0.73ml Intravenous; Subcutaneous Accord Healthcare S.L.U. 2022-06-09 Not applicable EU Accofil Injection, solution 30000000 U/0.5ml Intravenous; Subcutaneous Accord Healthcare S.L.U. 2016-09-07 Not applicable EU Accofil Injection, solution 48000000 U/0.5ml Intravenous; Subcutaneous Accord Healthcare S.L.U. 2016-09-07 Not applicable EU Accofil Injection, solution 12000000 U/0.2ml Intravenous; Subcutaneous Accord Healthcare S.L.U. 2022-06-08 Not applicable EU Accofil Injection, solution 30000000 U/0.5ml Intravenous; Subcutaneous Accord Healthcare S.L.U. 2016-09-07 Not applicable EU
Categories
- ATC Codes
- L03AA02 — Filgrastim
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antineoplastic and Immunomodulating Agents
- Biological Factors
- Colony-Stimulating Factors
- Glycoconjugates
- Glycoproteins
- Granulocyte Colony-Stimulating Factors
- Hematologic Agents
- Hematopoietic Cell Growth Factors
- Increased Myeloid Cell Production
- Leukocyte Growth Factor
- Peptides
- Proteins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- PVI5M0M1GW
- CAS number
- 121181-53-1
References
- Synthesis Reference
Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu, "Method of producing a polypeptide having human granulocyte colony stimulating factor activity." U.S. Patent US5994518, issued February, 1988.
US5994518- General References
- Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C: Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547. [Article]
- Panopoulos AD, Watowich SS: Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008 Jun;42(3):277-88. doi: 10.1016/j.cyto.2008.03.002. Epub 2008 Apr 8. [Article]
- Aghedo BO, Gupta V: Filgrastim . [Article]
- Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH: A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. [Article]
- Boxer L, Dale DC: Neutropenia: causes and consequences. Semin Hematol. 2002 Apr;39(2):75-81. doi: 10.1053/shem.2002.31911. [Article]
- Abdolzade-Bavil A, von Kerczek A, Cooksey BA, Kaufman T, Krasney PA, Pukac L, Gorlach M, Lammerich A, Scheckermann C, Allgaier H, Shen WD, Liu PM: Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. J Clin Pharmacol. 2016 Feb;56(2):186-94. doi: 10.1002/jcph.578. Epub 2015 Sep 1. [Article]
- Scholz M, Ackermann M, Engel C, Emmrich F, Loeffler M, Kamprad M: A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Prolif. 2009 Dec;42(6):813-22. doi: 10.1111/j.1365-2184.2009.00638.x. Epub 2009 Aug 17. [Article]
- DailyMed Label: NEUPOGEN (filgrastim) injection, for subcutaneous or intravenous use [Link]
- DailyMed Label; GRANIX (tbo-filgrastim) injection, for subcutaneous use [Link]
- EMA Summary of Product Characteristics: HEXAL (filgrastim) subcutaneous or intravenous injection [Link]
- Hospira Safety Data Sheet: NIVESTYM (Filgrastim-aafi) [Link]
- Drugs@FDA: Zarxio (filgrastim-sndz) [Link]
- Business Wire News: Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow) [Link]
- FDA Approved Drug Products: NEUPOGEN® (filgrastim) injection, for subcutaneous or intravenous use [Link]
- FDA Approved Drug Products: NIVESTYM™ (filgrastim-aafi) injection, for subcutaneous or intravenous use [Link]
- External Links
- UniProt
- P09919
- Genbank
- X03438
- KEGG Drug
- D03235
- PubChem Substance
- 46505833
- 1433764
- ChEMBL
- CHEMBL1201567
- Therapeutic Targets Database
- DAP000113
- PharmGKB
- PA449626
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Filgrastim
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Basic Science Head And Neck Cancer / Malignant Melanoma 1 somestatus stop reason just information to hide Not Available Approved for Marketing Not Available Autologous Stem Cell Transplantation 1 somestatus stop reason just information to hide Not Available Completed Not Available Acute Lymphoblastic Leukemia (ALL) 1 somestatus stop reason just information to hide Not Available Completed Not Available Breast Cancer / Colon Cancer / Lung Cancer / Non-Hodgkin's Lymphoma (NHL) / Ovarian Cancer / Pancreatic Cancer 1 somestatus stop reason just information to hide Not Available Completed Not Available Breast Cancer / Lung Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amgen Inc.
- Physicians Total Care Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous; Subcutaneous 12000000 U/0.2ml Injection, solution Intravenous; Subcutaneous 30000000 U/0.5ml Injection, solution Intravenous; Subcutaneous 48000000 U/0.5ml Injection, solution Intravenous; Subcutaneous 70000000 U/0.73ml Injection, solution Parenteral; Subcutaneous 12 MU/0.2ml Injection, solution Parenteral; Subcutaneous 70 MU/0.73ml Injection Parenteral 30 MIO.E./0.5ML Injection Parenteral 0.5 ML Injection, solution Intravenous; Subcutaneous 300 mcg/0.5mL Injection Parenteral 30 MIO E/0.5ML Injection Parenteral 48 MIO.E./0.5ML Injection, solution Intravenous; Subcutaneous 480 mcg/0.5mL Injection Parenteral 48 MIO E/0.5ML Solution Intravenous; Subcutaneous 480 mcg Solution Parenteral 300.0 mcg Injection, solution Intravenous; Subcutaneous 30 MIU Injection, solution Intravenous; Subcutaneous 48 MIU Solution Subcutaneous 300.000 mg Solution Intravenous; Subcutaneous 300 mcg Solution Intravenous; Subcutaneous 30000000 mcg Injection, solution Intravenous; Subcutaneous 60 MU/ml Injection, solution Intravenous; Subcutaneous 96 MU/ml Injection Parenteral 0.3 mg Injection Parenteral 0.48 mg Injection Intravenous Injection Intravenous 30 miu/0.5ml Injection Intravenous 48 miu/0.5ml Solution 300 mcg/1ml Injection, solution Subcutaneous 300 ug/1mL Injection, solution Subcutaneous 480 ug/1.6mL Injection, solution, concentrate Intravenous; Subcutaneous 30 MU/ml Injection, solution, concentrate Subcutaneous 300 mcg Injection, solution, concentrate Subcutaneous 480 mcg Solution Subcutaneous 300.00 mcg Injection, solution Subcutaneous 48 MU/0.5ml Solution Intravenous; Subcutaneous 300 mcg / 0.5 mL Solution Intravenous; Subcutaneous 480 mcg / 0.8 mL Solution Parenteral 300 mcg Solution Subcutaneous 300 mcg Solution Subcutaneous 480 mcg Injection; injection, solution 300 MCG/ML Injection Intravenous; Subcutaneous 15 miu Injection Intravenous; Subcutaneous Injection Intravenous; Subcutaneous 30 miu Injection, solution 480 mcg/ml Injection Intravenous; Subcutaneous 30 miu/ml Injection 300 mcg/ml Solution Subcutaneous 300.00 µg Injection, solution 30 MU Injection, solution 48 MU Injection, solution Intravenous 300 ug/0.5mL Injection, solution Intravenous 300 ug/1mL Injection, solution Intravenous 480 ug/0.8mL Solution Intravenous; Subcutaneous 300 mcg / mL Solution Intravenous; Subcutaneous 600 mcg / mL Solution Subcutaneous 0.300 mg Injection, solution Intravenous; Subcutaneous 0.3 MG/ML Injection Parenteral 300 µg/0.5ml Injection Parenteral 30 MIO.E. Injection Parenteral 300 UG/1ML Injection Parenteral 480 µg/0.5ml Injection Parenteral 48 MIO.E. Injection Parenteral 480 UG Injection Parenteral 480 UG/0.5ML Injection Intravenous; Subcutaneous 300 mcg/ml Injection Intravenous; Subcutaneous 480 mcg/1.6ml Injection Intravenous; Subcutaneous 30 mu/0.5ml Injection Intravenous; Subcutaneous 48 mu/0.5ml Injection, solution Intravenous; Subcutaneous 30 MU/0.5ML Injection; solution Intravenous; Subcutaneous 30 miu/0.5ml Injection; solution Intravenous; Subcutaneous 48 miu/0.5ml Solution Intravenous; Subcutaneous 30 millions of units Injection, solution 480 mcg/1vial Injection, solution Intravenous; Subcutaneous 12 MU/0.2ml Injection, solution Intravenous; Subcutaneous 12000000 [units of filgrastim]/0.2mL Injection, solution Intravenous; Subcutaneous 30000000 [units of filgrastim]/0.5mL Injection, solution Intravenous; Subcutaneous 48 MU/0.5ml Injection, solution Intravenous; Subcutaneous 48000000 [units of filgrastim]/0.5mL Injection Parenteral 12 MIO E/0.2ML Injection Parenteral 0.2 ML Injection, solution Intravenous; Subcutaneous 120 mcg/0.2ml Injection, solution Intravenous drip; Subcutaneous 0.120 mg/0.2ml Injection, solution Intravenous Solution Intravenous drip; Subcutaneous 0.300 mg/0.5ml Injection Parenteral 05 ML Solution Intravenous drip; Subcutaneous 0.480 mg/0.5ml Injection, solution 120 mcg/0.2ml Injection, solution Intravenous; Subcutaneous 300 ug/1mL Injection, solution Intravenous; Subcutaneous 480 ug/1.6mL Injection, solution Subcutaneous 300 ug/0.5mL Injection, solution Subcutaneous 480 ug/0.8mL Solution Intravenous; Subcutaneous 480 mcg / 1.6 mL Solution Intravenous; Subcutaneous 300 cg Injection, solution Intravenous; Subcutaneous 30 MIU/0.5ml Injection, solution Intravenous; Subcutaneous 48 MIU/0.8ml Injection Parenteral 30 M UI/0.5 ml Injection Parenteral 48 M UI/0.8 ml Injection Parenteral 0.8 ML Injection, solution Intravenous; Subcutaneous 30 MUI/0.5ml Injection, solution Intravenous; Subcutaneous 300 µg/0.5 ml Injection, solution Intravenous; Subcutaneous 48 MUI/0.8ml Injection, solution Intravenous; Subcutaneous 480 µg/0.8 ml Injection, solution Intravenous; Subcutaneous 300 ug/0.5mL Injection, solution Intravenous; Subcutaneous 480 ug/0.8mL Solution Subcutaneous 300.000 mcg Injection, solution 480 mcg/1ml Injection Parenteral 30 MIO E./0.5ML Solution Intravenous; Subcutaneous 300 mcg/0.5ml Injection Parenteral 48 MIO E./0.5ML Solution Intravenous; Subcutaneous 480 mcg/0.5ml Injection, solution Intravenous; Subcutaneous 0.3 mg/0.5ml Solution Intravenous; Subcutaneous 30 million IU Injection, solution 10000 iu/10ml Injection, solution 300 mcg/0.5ml Injection, solution 480 mcg/0.5ml Solution 300 mcg/1vial Solution 480 mcg/1vial Injection, solution 300 mcg/ml Injection, solution 300 mcg/1ml - Prices
Unit description Cost Unit Neupogen 480 mcg/0.8ml Solution 1 Box Contains Ten 0.8ml Syringes 4998.24USD box Neupogen 480 mcg/1.6ml Solution 1 Box Contains Ten 1.6ml Syringes 4554.58USD box Neupogen 300 mcg/0.5ml Solution 1 Box Contains Ten 0.5ml Syringes 3138.1USD box Neupogen 480 mcg/1.6 ml vial 437.94USD ml Neupogen 300 mcg/ml vial 286.04USD vial DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA1341537 No 2007-07-31 2024-07-31 Canada CA1339071 No 1997-07-29 2014-07-29 Canada
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 100 https://www.msds.amgen.com/-/media/Themes/Amgen/msds-amgen-com/msds-amgen-com/documents/neupogen_safety_data_sheet_20130218_rev_3.pdf isoelectric point 5.65 Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Stimulator
- General Function
- Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface
- Specific Function
- cytokine binding
- Gene Name
- CSF3R
- Uniprot ID
- Q99062
- Uniprot Name
- Granulocyte colony-stimulating factor receptor
- Molecular Weight
- 92155.615 Da
References
- Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. [Article]
- Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanne-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ: Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9. [Article]
- Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients]. Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. [Article]
- Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. [Article]
- Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. [Article]
- EMA label [File]
- TBO filgrastim [File]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Serine protease that modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis (PubMed:15140022). Promotes cleavage of GSDMB, thereby inhibiting pyroptosis (PubMed:36899106). Capable of killing E.coli but not S.aureus in vitro; digests outer membrane protein A (ompA) in E.coli and K.pneumoniae (PubMed:10947984)
- Specific Function
- cytokine binding
- Gene Name
- ELANE
- Uniprot ID
- P08246
- Uniprot Name
- Neutrophil elastase
- Molecular Weight
- 28517.81 Da
References
- Abdolzade-Bavil A, von Kerczek A, Cooksey BA, Kaufman T, Krasney PA, Pukac L, Gorlach M, Lammerich A, Scheckermann C, Allgaier H, Shen WD, Liu PM: Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. J Clin Pharmacol. 2016 Feb;56(2):186-94. doi: 10.1002/jcph.578. Epub 2015 Sep 1. [Article]
- Scholz M, Ackermann M, Engel C, Emmrich F, Loeffler M, Kamprad M: A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Prolif. 2009 Dec;42(6):813-22. doi: 10.1111/j.1365-2184.2009.00638.x. Epub 2009 Aug 17. [Article]
Drug created at June 13, 2005 13:24 / Updated at September 02, 2024 13:51